Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood diseases
Pharma
Agios charts broad path for oral thalassemia med after trial win
The positive data showed mitapivat’s potential to become the first oral therapy for nontransfusion-dependent thalassemia, Agios CEO said.
Angus Liu
Jan 3, 2024 10:49am
Novartis shows strong Fabhalta results in another blood disorder
Dec 11, 2023 11:20am
Takeda keeps approval rolling with FDA nod for Adzynma
Nov 9, 2023 3:40pm
Genentech exec sheds more light on plans for biologics plant
Feb 21, 2023 9:50am
Vertex teases launch plans for first CRISPR gene editing therapy
Feb 8, 2023 2:55pm
'Commercial debate' looms over Blueprint's Ayvakit expansion
Aug 17, 2022 11:06am